Cargando…

Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective

Ongoing advances in precision cancer therapy have increased the number of molecularly targeted and immuno-oncology agents for a variety of cancers, many of which have been associated with a risk of pulmonary complications, among the most concerning being drug-induced interstitial lung disease/pneumo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Henning, Jan-Willem, Brezden-Masley, Christine, Gelmon, Karen, Chia, Stephen, Shapera, Shane, McInnis, Micheal, Rayson, Daniel, Asselah, Jamil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529919/ https://www.ncbi.nlm.nih.gov/pubmed/37754497 http://dx.doi.org/10.3390/curroncol30090582

Ejemplares similares

Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
por: Azar, Ibrahim, et al.
Publicado: (2021)

Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
por: Chiu, Joanne Wing Yan, et al.
Publicado: (2023)

Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients
por: Wekking, D., et al.
Publicado: (2023)

Trastuzumab deruxtecan for breast cancer
Publicado: (2022)

Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective
por: Ferrario, Cristiano, et al.
Publicado: (2022)

An unusual case of interstitial lung disease: Revisiting peribronchiolar metaplasia interstitial lung disease (PBM‐ILD)
por: Jung, Flora, et al.
Publicado: (2023)

Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain
por: Rayson, Daniel, et al.
Publicado: (2022)

Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895”
por: Rayson, Daniel, et al.
Publicado: (2023)

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer
por: Jänne, Pasi A., et al.
Publicado: (2022)

Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer
por: Rugo, H.S., et al.
Publicado: (2022)

Correction: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer
Publicado: (2022)

Safety of trastuzumab deruxtecan: A meta‐analysis and pharmacovigilance study
por: Guo, Zihan, et al.
Publicado: (2022)

HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review
por: Jerzak, Katarzyna J., et al.
Publicado: (2023)

Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer
por: Kotani, Daisuke, et al.
Publicado: (2021)

Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
por: Indini, Alice, et al.
Publicado: (2021)

Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan
por: Moss, Nelson S, et al.
Publicado: (2022)

Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
por: Kabraji, Sheheryar, et al.
Publicado: (2023)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer
por: Makhlin, Igor, et al.
Publicado: (2022)

Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy
por: McNamara, Blair, et al.
Publicado: (2023)

Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
por: DiPeri, Timothy P., et al.
Publicado: (2023)

Adverse Event Profile Differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: A Real-world, Pharmacovigilance Study
por: Liu, Fen, et al.
Publicado: (2023)

Two cases of trastuzumab deruxtecan‐induced interstitial lung disease in advanced breast cancer
por: Gocho, Kyoko, et al.
Publicado: (2022)

Successful Trastuzumab-Deruxtecan Rechallenge After Interstitial Lung Disease: A Case Report
por: de Weger, Vincent A., et al.
Publicado: (2023)

Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan
por: Baba, Tomohisa, et al.
Publicado: (2023)

Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines
por: Simmons, Christine, et al.
Publicado: (2022)

Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases
por: Higashiyama, Nicole, et al.
Publicado: (2020)

Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer
por: Shitara, Kohei, et al.
Publicado: (2021)

Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials
por: Xu, Hanyue, et al.
Publicado: (2022)

A Case of HER2 Mutated Colorectal Cancer Treated Successfully With Fam-Trastuzumab Deruxtecan
por: Reddy, Aswanth, et al.
Publicado: (2023)

Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
por: Alder, Laura, et al.
Publicado: (2023)

Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer
por: Shi, Demin, et al.
Publicado: (2023)

Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
por: Antonarelli, G., et al.
Publicado: (2023)

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors
por: Takahashi, Shunji, et al.
Publicado: (2021)

Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
por: Nakajima, Hiromichi, et al.
Publicado: (2022)

Real-World Data of Trastuzumab Deruxtecan for Advanced Gastric Cancer: A Multi-Institutional Retrospective Study
por: Matsumoto, Toshihiko, et al.
Publicado: (2022)

Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape
por: Adams, E., et al.
Publicado: (2021)

Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors
por: Yin, Ophelia, et al.
Publicado: (2020)

Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies
por: Powell, C.A., et al.
Publicado: (2022)

Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan
por: Bardia, Aditya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6bkaienfral817us51e6ngqgql